Quantum computing, with its superior computational capabilities compared to classical approaches, holds the potential to revolutionize numerous scientific domains, including pharmaceuticals. However, the application of quantum computing for drug discovery has primarily been limited to proof-of-concept studies, which often fail to capture the intricacies of real-world drug development challenges. In this study, we diverge from conventional investigations by developing a hybrid quantum computing pipeline tailored to address genuine drug design problems. Our approach underscores the application of quantum computation in drug discovery and propels it towards more scalable system. We specifically construct our versatile quantum computing pipeline to address two critical tasks in drug discovery: the precise determination of Gibbs free energy profiles for prodrug activation involving covalent bond cleavage, and the accurate simulation of covalent bond interactions. This work serves as a pioneering effort in benchmarking quantum computing against veritable scenarios encountered in drug design, especially the covalent bonding issue present in both of the case studies, thereby transitioning from theoretical models to tangible applications. Our results demonstrate the potential of a quantum computing pipeline for integration into real world drug design workflows.
Quantum computing, with its superior computational capabilities compared to classical approaches, holds the potential to revolutionize numerous scientific domains, including pharmaceuticals. However, the application of quantum computing for drug discovery has primarily been limited to proof-of-concept studies, which often fail to capture the intricacies of real-world drug development challenges. In this study, we diverge from conventional investigations by developing a hybrid quantum computing pipeline tailored to address genuine drug design problems. Our approach underscores the application of quantum computation in drug discovery and propels it towards more scalable system. We specifically construct our versatile quantum computing pipeline to address two critical tasks in drug discovery: the precise determination of Gibbs free energy profiles for prodrug activation involving covalent bond cleavage, and the accurate simulation of covalent bond interactions. This work serves as a pioneering effort in benchmarking quantum computing against veritable scenarios encountered in drug design, especially the covalent bonding issue present in both of the case studies, thereby transitioning from theoretical models to tangible applications. Our results demonstrate the potential of a quantum computing pipeline for integration into real world drug design workflows.
Quantum computing, with its superior computational capabilities compared to classical approaches, holds the potential to revolutionize numerous scientific domains, including pharmaceuticals. However, the application of quantum computing for drug discovery has primarily been limited to proof-of-concept studies, which often fail to capture the intricacies of real-world drug development challenges. In this study, we diverge from conventional investigations by developing an advanced quantum computing pipeline tailored to address genuine drug design problems. Our approach underscores the pragmatic application of quantum computation and propels it towards practical industrial adoption. We specifically construct our versatile quantum computing pipeline to address two critical tasks in drug discovery: the precise determination of Gibbs free energy profiles for prodrug activation involving covalent bond cleavage, and the accurate simulation of covalent bond interactions. This work serves as a pioneering effort in benchmarking quantum computing against veritable scenarios encountered in drug design, especially the covalent bonding issue present in both of the case studies, thereby transitioning from theoretical models to tangible applications. Our results demonstrate the potential of a quantum computing pipeline for integration into real world drug design workflows.
The integration of quantum computing in drug discovery has the potential to revolutionize pharmaceutical research by significantly enhancing molecular simulations, drug screening, and optimization processes. Traditional computational methods often struggle with the complexity of molecular interactions, leading to high costs and extended timelines in drug development. Quantum computing, with its ability to process complex calculations exponentially faster than classical computers, offers innovative solutions to these challenges. This chapter explores the fundamentals of quantum computing, its application in pharmaceutical research, and real-world case studies from leading organizations. It also discusses existing challenges, potential solutions, and future directions for adopting quantum computing in drug discovery. By addressing key technical, ethical, and regulatory aspects, this chapter provides a comprehensive analysis of how quantum technologies can accelerate and optimize the drug discovery pipeline.
This study examines how quantum computing (QC) is being applied to molecular design and drug discovery. This study aims to investigates how QC surpasses classical limitations, focusing on empirical performance in precision, accuracy, and optimisation tasks. Study design use PRISMA 2009 guidelines, 15 empirical studies (2020-2025) were included. Data were extracted on the drug-discovery stage, the algorithm used, evaluation metrics, benefits, and limitations. The findings show QC outperforms classical methods particularly through hybrid quantum–classical models. Thirteen studies reported superior gains, including AUC–ROC values of 0.80–0.95, +30% improvement in drug-likeness (QED), +6% increase in prediction accuracy, and up to 99% accuracy in drug–target interaction tasks. However, noisy intermediate-scale quantum (NISQ) hardware limitations and poor scalability limit real-world deployment, due to noise, and limited qubit counts. Consequently, current performance results are largely simulation-based rather than hardware-validated. In contrast to prior algorithm-centric reviews, this study provides a consolidated empirical synthesis and proposes a hybrid quantum–classical pipeline that maps high-performing algorithms across the drug discovery workflow under NISQ-era constraints. These findings inform pharmaceutical research and development by identifying realistic adoption pathways and the boundaries of current technological readiness.
Quantum computing promises to be a game changer for drug discovery and battery development as it will enable simulations of complex molecular and material systems not possible in classical regimes. Here, we introduce a hardware-aware, hybrid quantum-classical framework designed for practical pharmaceutical and energy problems. Extending state-of-the-art results from quantum machine learning, quantum-inspired optimization, and domain-specific datasets, the model improves both scalability and accuracy as well as interpretability. The proposed method is validated from real-drug and battery chemistry with advantages over the traditional method. This interdisciplinary breakthrough tackles major drawbacks of current quantum approaches and provides a realistic pathway towards industrial implementation in chemistry-led innovation.
The pharmaceutical industry relies heavily on the drug discovery process to develop new medications that can help treat various diseases. This process is highly crucial but also very time-consuming, as it involves screening a massive number of chemical compounds to identify those that can be developed into effective treatments. Traditional computing methods are often inadequate for this task due to the complexity and vastness of the data involved. Quantum computing is an emerging field that has gained significant attention in recent years due to its ability to perform complex computations at a much faster pace than classical computers. Quantum computing uses the principles of quantum mechanics, which differ significantly from classical computing. Drug discovery involves a process of identifying new drugs with the desired biological activity to treat specific diseases. This process can be quite lengthy, time-consuming, and expensive, often taking many years to develop a single drug. However, quantum computing has the potential to revolutionize the drug discovery process. Its ability to perform complex calculations quickly and efficiently could significantly speed up the drug discovery process, making it more cost-effective and accurate. Quantum computing's potential in drug discovery requires further research to fully understand and develop practical applications. The use of quantum computing requires the development of specialized algorithms and software tailored to quantum computing. Further investment in research and development is needed to fully leverage the potential of this technology. This paper explores the potential of quantum computing in drug discovery. We will analyze the benefits of using quantum computing in drug discovery, including faster and more accurate data processing, improved optimization, and more efficient screening of chemical compounds. Our paper will also discuss the challenges and limitations that need to be addressed to fully leverage the potential of quantum computing in drug discovery. This will include discussing potential applications of quantum computing in drug discovery, as well as the need for further investment in research and development to fully realize the potential of this technology. Overall, our paper will provide a comprehensive analysis of the potential of quantum computing in drug discovery, exploring both the benefits and challenges associated with this technology and providing recommendations for future research and development.
Quantum computers are recently being developed in wide varieties, but the computational results from quantum computing have been largely confined to constructing artificial assignments. The applications of quantum computers to real-world problems are still an active area of research. However, challenges arise when the limits of scale and complexity in biological problems are pushed, which has affected drug discovery. The fast-evolving quantum computing technology has transformed the computational capabilities in drug research by searching for solutions for complicated and tedious calculations. Quantum computing (QC) is exponentially more efficient in drug discovery, treatment, and therapeutics, generating profitable business for the pharmaceutical industry. In principle, it can be stated that quantum computing can solve complex problems exponentially faster than classical computing. Here it is needed to mention that QC will not be able to take on every task that classical computers perform—at least not now. It may be classical and quantum-coupled computational technologies combined with machine learning (ML) and artificial intelligence (AI) will solve each task in the future. This review is an overview of quantum computing, which may soon revolutionize the pharmaceutical industry in drug discovery.